Sorry, you need to enable JavaScript to visit this website.

Learning About XARELTO® | XARELTO® (rivaroxaban) Welcome Kit

Prescription Icon A potentially life-threatening complication. Starting therapy. All of this can be daunting and overwhelming. But you can be reassured that, together with a few tips, support, and commitment, it’s possible to start on the right track. First things first, be sure to fill your XARELTO® prescription if you haven’t yet.

What is XARELTO®?

XARELTO® belongs to a group of medicines called direct oral anticoagulants, or DOACs for short. Like other DOACs, XARELTO® has no known dietary restrictions and no requirements for frequent blood tests.

How does XARELTO® work?

XARELTO® slows your body's ability to clot by selectively blocking one of the clotting factors found in your blood—an enzyme called Factor Xa ("10a").

Treating DVT and PE with XARELTO®

XARELTO® is a prescription medication used to treat and reduce the risk of deep vein thrombosis (DVT) and pulmonary embolism (PE) from happening again.

Treats DVT and PE

Almost 98% did not have
Almost 98% did not have another DVT or PE

In two clinical studies,

almost 98% of adults being treated for a DVT or PE with XARELTO® did not have another one.*

*In the EINSTEIN DVT and EINSTEIN PE studies, XARELTO® was demonstrated to be similar to enoxaparin/vitamin L antagonist for the primary composite endpoint of time to first occurrence of recurrent DVT or nonfatal or fatal PE (EINSTEIN DVT HR (95% CI): 0.68 (0.44, 1.04); EINSTEIN PE HR (95% CI): 1.12 (0.75, 1.68)].

2.1% of patients treated with XARELTO® experienced another PE vs 1.8% of patients treated with enoxaparin/vitamin K antagonist (EINSTEIN PE). Patients were followed for an average length of 208 days. People taking XARELTO® to treat a DVT or PE showed a major bleeding rate of 1% vs 1.7% with enoxaparin and vitamin K antagonist.

Reduce the risk of another DVT and PE from happening again

Almost 99% did not have
Almost 99% did not have another DVT or PE

After 6 months of initial treatment.

In another clinical study,

almost 99% of adults taking XARELTO® did not have another DVT or PE after 6 months of initial treatment for blood clots. XARELTO® was superior to aspirin in reducing the risk of DVT/PE. After receiving treatment for blood clots for at least 6 months, 1.2% of patients on XARELTO® experienced another DVT or PE vs 4.4% on aspirin at 1 year (EINSTEIN CHOICE). Less than 1% of patients taking XARELTO® experienced major bleeding. which is similar to the rate of major bleeding in patients taking aspirin to reduce their risk of recurrent DVT or PE.